Product Name: PDK1 (537-552)
Product Number: PE-01BEL85
| Size: | 1 mg | Price: | 86.00 | |
| 5 mg | $US | 187.00 | ||
| 20 mg | 331.00 |
Peptide Name: PDK1 (537-552)
Product Use: Services as a blocking peptide for use with the PDK1-CT rabbit polyclonal antibody (Cat. No.: AB-NK126-3) that is also available from Kinexus. The peptide sequence is located in the C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CRKIQEVWRQRYQSHPDA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2299.6 Da
Peptide Purity Percent after Synthesis and Purification: >80
Product Use: Services as a blocking peptide for use with the PDK1-CT rabbit polyclonal antibody (Cat. No.: AB-NK126-3) that is also available from Kinexus. The peptide sequence is located in the C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CRKIQEVWRQRYQSHPDA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2299.6 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PDK1 pan-specific antibody (Cat. No.: AB-NK126-3)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PDK1 pan-specific antibody (Cat. No.: AB-NK126-3)
Scientific Background: PDK1 (PDPK1) is a protein-serine/threonine kinase of the AGC group and PKB family. It activates, via phosphorylation, many members of the AGC family of protein kinases. Tyrosine phosphorylation induced by pervanadate in PDK1 can be partly reduced through a Y9F mutation in PDK1. Activation of PDK1 can be inhibited through a S241A mutation. Its phosphotransferase activity can be reduced 3-fold with a A277V mutation. MELK-mediated phosphorylation can be inhibited through a T354A mutation. General phosphotransferase activity can be reduced through either a Y373F, or a Y376F mutation. PDK1 phosphorylation of MAP3K5 can be ablated through the S394A and S398A mutations. Membrane localization via PDGF can be inhibited through a R474A mutation. PKB has been observed to be phosphorylated more via a T513E mutation. Tyrosine phosphorylation induced by pervanadate in PDK1 can be partly reduced through a Y9F mutation in PDK1. Activation of PDK1 can be inhibited through a S241A mutation. Its phosphotransferase activity can be reduced 3-fold with a A277V mutation. MELK-mediated phosphorylation can be inhibited through a T354A mutation. PDK1 is important in mediating migration and metastasis of breast cancer cells.
© Kinexus Bioinformatics Corporation 2017